Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance

被引:43
|
作者
Loblaw, Andrew [1 ]
Zhang, Liying
Lam, Adam
Nam, Robert [2 ]
Mamedov, Alexandre
Vesprini, Danny [1 ]
Klotz, Laurence [2 ]
机构
[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON M4N 3M5, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON M4N 3M5, Canada
来源
JOURNAL OF UROLOGY | 2010年 / 184卷 / 05期
关键词
risk assessment; prostatic neoplasms; prostate-specific antigen; kinetics; BEAM RADIATION-THERAPY; RADICAL PROSTATECTOMY; CURATIVE INTENT; MANAGEMENT; TRIAL;
D O I
10.1016/j.juro.2010.06.101
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We determined the proportion of men with nonprogressive prostate cancer on active surveillance who had a trigger for treatment using various measures of prostate specific antigen kinetics. Materials and Methods: A prospective phase II study of patients with favorable clinical parameters (stage T1b-T2b N0M0, Gleason sum 7 or less, prostate specific antigen 15 ng/ml or less) on active surveillance was initiated in 1995. Those patients considered at high risk for progression were offered radical intervention. The remaining patients were closely monitored and formed the cohort for this study. We calculated the proportion and frequency of patients who had a trigger for treatment based on the various prostate specific antigen triggers (prostate specific antigen doubling time, prostate specific antigen velocity, prostate specific antigen threshold). Results: Of 450 patients followed on surveillance 305 remained on active surveillance without definitive intervention. None of these 305 patients have died of prostate cancer or have had symptomatic metastatic disease develop. Median followup was 6.8 years. The proportion of patients who would have had a trigger for treatment ranged from 14% to 42% for the threshold triggers, 37% to 50% for the prostate specific antigen doubling time triggers and 42% to 84% for the velocity triggers. Conclusions: Almost all of the prostate specific antigen triggers examined in this study would have led to high rates of trigger for treatment. More work is needed to identify a trigger that better strikes the balance between recommending treatment for patients at high risk for progression and minimizing treatment for those at low risk for progression.
引用
收藏
页码:1942 / 1946
页数:5
相关论文
共 50 条
  • [1] Comparing PSA triggers for treatment for men with prostate cancer on active surveillance
    Loblaw, A.
    Zhang, L.
    Klotz, L.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S10 - S10
  • [2] Active surveillance in prostate cancer: patient selection and triggers for intervention
    Lees, Kathryn
    Durve, Meeta
    Parker, Chris
    CURRENT OPINION IN UROLOGY, 2012, 22 (03) : 210 - 215
  • [3] COMPARING PSA TRIGGERS FOR TREATMENT FOR MEN WITH NON-PROGRESSIVE PROSTATE CANCER ON ACTIVE SURVEILLANCE
    Klotz, Laurence
    Zhang, Liying
    Nam, Robert
    Loblaw, Andrew
    JOURNAL OF UROLOGY, 2010, 183 (04): : E96 - E96
  • [4] VARIATION OF SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS FOR MEN WITH PROSTATE CANCER MANAGED WITH ACTIVE SURVEILLANCE
    Ehdaie, Behfar
    Poon, Bing Ying
    Sjoberg, Daniel
    Vickers, Andrew
    Sternberg, Itay
    Laudone, Vincent
    Touijer, Karim
    Eastham, James
    Scardino, Peter
    JOURNAL OF UROLOGY, 2014, 191 (04): : E859 - E860
  • [5] Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era
    Ercole, Barbara
    Marietti, Sarah R.
    Fine, Judith
    Albertsen, Peter C.
    JOURNAL OF UROLOGY, 2008, 180 (04): : 1336 - 1339
  • [6] Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance
    Ehdaie, Behfar
    Poon, Bing Ying
    Sjoberg, Daniel D.
    Recabal, Pedro
    Laudone, Vincent
    Touijer, Karim
    Eastham, James
    Scardino, Peter T.
    BJU INTERNATIONAL, 2016, 118 (04) : 535 - 540
  • [7] Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing
    Overholser, Stephen
    Nielsen, Matthew
    Torkko, Kathleen
    Cwilka, Daniel
    Weaver, Brandi
    Shi, Xiaoyu
    Leach, Robin J.
    Hernandez, Javier
    Huang, Tim
    Thompson, Ian M., Jr.
    Thompson, Ian M., III
    JOURNAL OF UROLOGY, 2015, 194 (03): : 680 - 684
  • [8] The impact of reducing the frequency of prostate specific antigen (PSA) testing among men on active surveillance for prostate cancer
    Cooperberg, Matthew R.
    Newcomb, Lisa F.
    Brown, Elissa C.
    Zhao, Shanshan
    Feng, Ziding
    Brooks, James D.
    Lin, Daniel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Prostate Specific Antigen Utility and Anxiety in the Management of Prostate Cancer by Active Surveillance
    Anderson, Jake
    Fletcher, Jane
    Ricciardelli, Lina
    Burney, Susan
    Brooker, Joanne
    Frydenberg, Mark
    PSYCHO-ONCOLOGY, 2013, 22 : 312 - 312
  • [10] LONGITUDINAL FOLLOW-UP OF PROSTATE SPECIFIC ANTIGEN (PSA) AND PROSTATE CANCER ANTIGEN-3 (PCA3) IN MEN WITH STABLE DISEASE ON ACTIVE SURVEILLANCE
    Dangle, Pankaj
    Novakovic, Kristian
    Brendler, Charles
    Pruitt, Jaclyn
    Rabbitt, Sarah
    Du, Hongyan
    McGuire, Michael
    JOURNAL OF UROLOGY, 2012, 187 (04): : E659 - E660